Page last updated: 2024-11-11

neuromedin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

neuromedin B: decapeptide isolated from porcine spinal cord [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID53481579
MeSH IDM0115602

Synonyms (3)

Synonym
neuromedin b
gly-asn-leu-trp-ala-thr-gly-his-phe-met-nh2
(2s)-2-[(2r)-2-[(2s)-2-{2-[(2s,3r)-2-[(2r)-2-[(2r)-2-[(2s)-2-[(2r)-2-(2-aminoacetamido)-3-(c-hydroxycarbonimidoyl)propanamido]-4-methylpentanamido]-3-(1h-indol-3-yl)propanamido]propanamido]-3-hydroxybutanamido]acetamido}-3-(1h-imidazol-4-yl)propanamido]-3

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The pharmacological profiles obtained support receptor heterogeneity for BN-like peptides on this SCLC line, underscoring the need for thorough examination of dose-response relationships when investigating effects of BN analogues on intact cells."( Two bombesin analogues discriminate between neuromedin B- and bombesin-induced calcium flux in a lung cancer cell line.
Cowan, A; Daniel, JL; Ryan, RR,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (246)

TimeframeStudies, This Drug (%)All Drugs %
pre-199040 (16.26)18.7374
1990's105 (42.68)18.2507
2000's40 (16.26)29.6817
2010's47 (19.11)24.3611
2020's14 (5.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.79%)5.53%
Reviews11 (4.37%)6.00%
Case Studies1 (0.40%)4.05%
Observational0 (0.00%)0.25%
Other238 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]